Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Share 2021 Growth Challenges, Opportunities and Future Trends 2027

The global dipeptidyl peptidase-4 (DPP-4) inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to boost the market growth include increasing incidences of diabetes, particularly type-2 diabetes, as well as an increase in obesity populations. Moreover, an increase in clinical trials on the DPP-4 drugs is another factor that is expected to accelerate the growth of the market during the forecast period. The prevalence of diabetes in 2019 across the globe was more than 463 million and is projected to increase during the forecast period as per the International Diabetes Federation (IDF). The dipeptidyl peptidase 4 (DPP-4) inhibitors support in the release of insulin secretion in the patients' body and regulate the sugar levels in the body. Hence, such factors are likely to enhance the growth of the market during the forecast period. However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors is restraining the growth of the market.



To Request a Sample of our Report on Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market: https://www.omrglobal.com/request-sample/dipeptidyl-peptidase-4-dpp-4-inhibitors-market

Tradjenta includes its combination Jentadueto and Jentadueto XR, a combination of linagliptin (Tradjenta) and metformin hydrochloride, for use in the treatment of type 2 diabetes. The type-2 diabetes drug, Tradjenta (linagliptin) was not launched in Germany due to the decision by the county's reimbursement authority, which concluded that it doesn't provide any additional benefits, compared to the medicines already on the market. In order to maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. Merck held the highest market share in the DPP-4 inhibitors market and is expected to maintain its position till 2022. After that, it may witness a decline in market share, due to the expected launch of a generic version of Sitagliptin in 2022.

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

· By Drug

Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape: Merck and Co., Inc., AstraZeneca plc, Eli Lilly and Co., and Boehringer Ingelheim GmbH, among others.

(Get 15% Discount on Buying this Report)

A full Report of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market is Available @ https://www.omrglobal.com/industry-reports/dipeptidyl-peptidase-4-dpp-4-inhibitors-market

Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Report by Segment

By Drug

• Januvia

• Onglyza/Kombiglyze

• Tradjenta

• Nesina

• Galvus

• Others

Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.